Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Cara Care has teamed up with the Consumer Healthcare Business Unit of Sanofi Germany to provide Sanofi’s Buscomint® bei Reizdarm drug with Cara Care’s digital companion app for digestive conditions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 22, 2020
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2015
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2014
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Abdominal Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2014
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2014
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms
Details : Hyoscine N-Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastrointestinal Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 01, 2014
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain
Details : Buscopan (Hyoscine Butylbromide) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Intestinal Diseases.
Product Name : Buscopan
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 27, 2013
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 28, 2012
Lead Product(s) : Hyoscine Butyl Bromide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
